| Buy or Sell |
| Buy it- Its going up |
|
50% |
[ 1 ] |
| Sell it- Its going down |
|
0% |
[ 0 ] |
| Short it -Its the Titanic |
|
0% |
[ 0 ] |
| Stay away-no reason to get invovled with |
|
50% |
[ 1 ] |
|
| Total Votes : 2 |
|
| Author |
Message
|
| geb9696 |
 Posted: Wed Jan 25, 2006 4:08 pm Post subject: Stock Research Bristol-Myers Squibb Co. (BMY) |
 |
|
Investing VP
|
| I figure my pick would be Bristol-Myers Squibb Co. who have had great advances in the research with Cancer and Rheumatoid Arthritis. I get news updates on all Rheumatoid Athritis and I got google alert that researchers in Korea have delevoped a drug that in testing with monkeys cures Rheumatoid Arthritis. This is groundbreaking news be RA is not curable in humans at this point. If this drug that cures the monkeys also works in humans it will be the only one of its kind. The research in Korea also discovered that the drugs may cure certain types of cancer. |
|
| Back to top |
|
 |
| frusnak |
| Posted: Wed Jan 25, 2006 4:25 pm Post subject: |
|
|
CFO
|
BMY@$21.97
52 week range -$20.70...$26.60
earning...$1.33
p/e 16
dividend $1.12
institutional ownership 67.4%
1.957 billion shares outstanding
99.3% float
511 sellers
382 buyers
the following article tells about earning problems for the next year...
NEW YORK (Reuters) - Bristol-Myers Squibb Co. on Wednesday posted a higher fourth-quarter profit due to lower taxes, but warned 2006 earnings may fall as much as 20 percent as its Pravachol cholesterol medicine and other drugs face generic competition.
The company, whose full-year 2005 profit fell 18 percent as a number of its drugs lost sales to generics, reaffirmed profit growth should resume in 2007.
Analysts cautioned, however, the rosy 2007 scenario assumes Bristol will block the U.S. launch of a generic form of Plavix, the $4 billion-a-year blood clot drug that is its biggest product.
U.S. regulators approved a cheaper copycat on Tuesday made by Canada's Apotex Inc. But analysts said it remained unclear whether Apotex will risk launching it before a court decision is rendered in its ongoing Plavix patent battle with Bristol and Sanofi-Aventis , its marketing partner.
"Bristol's earnings recovery depends on upholding the patent on Plavix, and the odds are only 60-40 in its favor," said Deutsche Bank analyst Barbara Ryan. "If Bristol loses, it would have to cut its dividend and even sell the company."
Bristol Chief Financial Officer Andrew Bonfield said the company is confident Plavix is protected until 2011 by a Sanofi patent. The court battle with Apotex is scheduled to begin in April.
Should Apotex launch its generic product and later lose the patent battle, it could be forced under law to pay Bristol three times its lost Plavix sales.
"My expectation is that Apotex will not launch at this point because it would be incredibly risky," said A.G. Edwards analyst Albert Rauch. Instead, he said Apotex would likely wait until a court decision is rendered, perhaps in a year or more.
DISAPPOINTING OUTLOOK
The New York-based drugmaker said it expects profit this year of $1.15 to $1.25 per share, excluding special items, or about 13 percent to 20 percent less than 2005. Analysts polled by Reuters Estimates, on average, expected $1.24 per share.
Shares of Bristol were up 57 cents, or 2.7 percent, to $21.92 in afternoon trade on the New York Stock Exchange. The stock fell 3.5 percent Tuesday after the Apotex drug was approved.
Fourth-quarter profit rose as a much lower tax rate and improved profit margins more than offset a decline in overall company sales.
The company earned $499 million, or 26 cents per share. That compared with $139 million, or 7 cents a share in the 2004 period, when it took a $575 million charge for taxes on overseas profits returned to the United States.
Excluding special items, Bristol-Myers earned 31 cents per share. Analysts, on average, expected 28 cents per share, according to Reuters Estimates.
Global company sales, which included nutritional products and medical devices, totaled $5.019 billion, about $100 million shy of Wall Street expectations. Sales of prescription drugs fell 3 percent to $4 billion in the quarter.
Pravachol sales dropped 18 percent to $584 million as doctors prescribed more-potent cholesterol treatments, such as Pfizer Inc.'s Lipitor or cheaper but less-potent drugs.
Pravachol sales are expected to suffer sharper declines after the drug loses its U.S. marketing exclusivity in April.
Sales of cancer drug Taxol were off 29 percent to $181 million as generic rivals became available in Europe, while sales of antibiotic Cefzil fell 16 percent to $75 million due to cheaper copycats.
Results were bolstered by Plavix, whose sales rose 11 percent to $1.06 billion. Sales of Avapro, a blood pressure drug also partnered with Sanofi, increased 7 percent to $277 million.
Bristol's Abilify schizophrenia drug, which does not cause weight gains seen with drugs such as Eli Lilly and Co.'s Zyprexa, jumped 17 percent to $224 million.
The stock fell 10.3 percent in 2005, compared with a 1 percent rise for the American Stock Exchange Pharmaceutical Index , which tracks large U.S. and European drugmakers.
Copyright 2006 Reuters |
|
| Back to top |
|
|
| geb9696 |
| Posted: Thu Jan 26, 2006 7:11 pm Post subject: |
|
|
Investing VP
|
| I guess nobody else want to research this stock. It did go up .65 today which is 2.96%. Not sure what everyone else thinks of the stock. |
|
| Back to top |
|
|
| poornewb |
| Posted: Thu Jan 26, 2006 8:26 pm Post subject: |
|
|
Investing Manager
|
It takes a long time to get a drug aproved even after youve got it tested on animals. If thats even BMY that is doing the testing. Doesnt sound like that great of a year for them either there p/e ratio is like 13 or 14 and the forward p/e ratio is 17. something.
I say hold off till 3rd quater when they SAY profits will come back in. |
|
| Back to top |
|
|
| frusnak |
| Posted: Fri Jan 27, 2006 12:14 am Post subject: |
|
|
CFO
|
yeah, I thought this would be a good idea to get more people involved and maybe find a stock or two to buy. We should invite anyone else who participates in this thread to pick one.
Cramer mentioned last night how drug companies would have a rough year due to the fact that a lot of their key products would be available to generic manufacturers. BMY looks like a good company it just isn't attractive for that reason. |
|
| Back to top |
|
|
| Dave Rathbun |
| Posted: Fri Jan 27, 2006 3:41 am Post subject: |
|
|
CFO
|
I didn't participate in this topic because I just don't have an interest in this area. I buy stocks in industries that I know because I work in a related field (technical) or because I'm interested in them. I'm not into drugs.  |
|
| Back to top |
|
|
| poornewb |
| Posted: Fri Jan 27, 2006 6:37 am Post subject: |
|
|
Investing Manager
|
|
| Back to top |
|
|
| frusnak |
| Posted: Sat Jan 28, 2006 12:48 am Post subject: |
|
|
CFO
|
Anyone want to pick one for this week??  |
|
| Back to top |
|
|
| nelaina |
| Posted: Sat Jan 28, 2006 4:42 am Post subject: |
|
|
CFO
|
| frusnak wrote: | | Anyone want to pick one for this week?? |
ive always got one in my pocket;) |
|
| Back to top |
|
|
| frusnak |
| Posted: Sat Jan 28, 2006 8:48 am Post subject: |
|
|
CFO
|
Well then nelaina, go for it. Monday??
Anyone else that wants to pick one after nelaina, can let us know. We need to get every one in on this so we can get some real investing ideas for einvesting's portfolio and anybody else who has a real investing portfolio. |
|
| Back to top |
|
|
|
|
 |
| Im Not Warren Buffett |
| Posted: Sat Jan 28, 2006 1:18 pm Post subject: |
|
|
CFO
|
| Dave Rathbun wrote: | | I didn't participate in this topic because I just don't have an interest in this area. I buy stocks in industries that I know because I work in a related field (technical) or because I'm interested in them. I'm not into drugs. |
I feel the same way. Investing in the big drug companies just don't interest me. I'm not completely opposed to medical/pharma, but if I did something there it would be a growth (!) play in a small company, where I'm looking for a big return. |
|
| Back to top |
|
|
| frusnak |
| Posted: Sun Apr 02, 2006 12:22 am Post subject: |
|
|
CFO
|
Here's where this stock is now...
1/25/06...$21.97
3/31/06...$24.61 |
|
| Back to top |
|
|
|
|
stock market game on the web. At eInvesting you compete for monthly cash prizes while you interact, make virtual dollars, purchase items, and trade in the realistic stock market simulator. We make investing FUN!
